Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04256317
Title A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Astex Pharmaceuticals, Inc.

acute myeloid leukemia

myelodysplastic/myeloproliferative neoplasm

myelodysplastic syndrome

chronic myelomonocytic leukemia



ASTX030 + Azacitidine

ASTX030 + Azacitidine + Cedazuridine

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.